Truist analyst Richard Newitter raised the firm’s price target on Zimmer Biomet to $153 from $137 but keeps a Hold rating on the shares after its Q1 earnings beat. The company is clearly executing and its new product momentum remains out in front, But from here, the question is whether Zimmer can drive leverage without outsized revenue growth, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet price target raised to $150 from $130 at Canaccord
- Zimmer Biomet price target raised to $156 from $141 at RBC Capital
- Zimmer Biomet price target raised to $160 from $144 at Raymond James
- Zimmer Biomet price target raised to $172 from $145 at Baird
- Zimmer Biomet price target raised to $160 from $145 at JMP Securities
